Loading
Surgeon who led De-ESCALaTE and PET-NECK, two trials that changed how HPV-positive throat cancer is treated and followed up.
Hisham Mehanna was chief investigator of De-ESCALaTE HPV, which showed cetuximab is inferior to cisplatin with radiotherapy in HPV-positive oropharyngeal cancer (mirroring RTOG 1016), and of PET-NECK, which showed PET-CT surveillance safely avoids neck dissection after chemoradiotherapy. He leads the UK's head and neck trials portfolio and the Institute of Head and Neck Studies and Education.
Shares University Hospitals Birmingham / University of Birmingham Cancer Research Centre and the tags surgery, uk.
Shares Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam) and the tag head-and-neck.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, surgery.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, de-escalation.
Shares University Hospitals Birmingham / University of Birmingham Cancer Research Centre and the tag uk.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, surgery.
Shares Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam) and the tag head-and-neck.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, surgery.